PharmacyCodes



Ramiprilum [Latin] en es it fr

Categoria

Ramiprilum [Latin] Nombres de marca, Ramiprilum [Latin] Analogos

Ramiprilum [Latin] Marca los nombres de mezcla

  • No information avaliable

    • Ramiprilum [Latin] Formula quimica

    C23H32N2O5

    Ramiprilum [Latin] RX enlace

    http://www.rxlist.com/cgi/generic/ramipril.htm

    Ramiprilum [Latin] FDA hoja

    Ramiprilum [Latin] MSDS (hoja de seguridad de materiales)

    Ramiprilum_[Latin] MSDS

    Ramiprilum [Latin] Sintesis de referencia

    EH Gold et al., Patente de EE.UU.. 4.587.258 (1967).

    Ramiprilum [Latin] Peso molecular

    416.511 g/mol

    Ramiprilum [Latin] Punto de fusion

    109 oC

    Ramiprilum [Latin] H2O Solubilidad

    3,5 mg / L

    Ramiprilum [Latin] Estado

    Solid

    Ramiprilum [Latin] LogP

    3.149

    Ramiprilum [Latin] Formas de dosificacion

    Cápsula

    Ramiprilum [Latin] Indicacion

    De diuréticos y digital en la insuficiencia cardíaca congestiva como tratamiento adyuvante y para su uso en la profilaxis de post MI.

    Ramiprilum [Latin] Farmacologia

    Ramipril es un enzima convertidora de angiotensina (ECA) similares al benazepril, fosinopril, y quinapril. Un profármaco inactivo, ramipril se convierte en ramiprilato en el hígado y se utiliza para tratar hipertensión y falla cardiaca, para reducir la proteinuria y enfermedad renal en pacientes con nefropatías, y para evitar accidente cerebrovascular, infarto de miocardio y muerte cardíaca en pacientes de alto riesgo.

    Ramiprilum [Latin] Absorcion

    El grado de absorción es al menos un 50-60% y no es significativamente influenciado por la presencia de alimentos en el tracto gastrointestinal, aunque la tasa de absorción se reduce.

    Ramiprilum [Latin] Toxicidad

    Las manifestaciones clínicas más probable sería síntomas atribuibles a la hipotensión. LD50 = 10.933 mg / kg (por vía oral en ratones).

    Ramiprilum [Latin] Informacion de Pacientes

    Pregnancy: Female patients of childbearing age should be told about the consequences of second- and third-trimester exposure to ACE inhibitors, and they should also be told that these consequences do not appear to have resulted from intrauterine ACE-inhibitor exposure that has been limited to the first trimester. These patients should be asked to report pregnancies to their physicians as soon as possible.

    Angioedema: Angioedema, including laryngeal edema, can occur with treatment with ACE inhibitors, especially following the first dose. Patients should be so advised and told to report immediately any signs or symptoms suggesting angioedema (swelling of face, eyes, lips, or tongue, or difficulty in breathing) and to take no more drug until they have consulted with the prescribing physician.

    Symptomatic Hypotension: Patients should be cautioned that lightheadedness can occur, especially during the first days of therapy, and it should be reported. Patients should be told that if syncope occurs, ramipril should be discontinued until the physician has been consulted.

    All patients should be cautioned that inadequate fluid intake or excessive perspiration, diarrhea, or vomiting can lead to an excessive fall in blood pressure, with the same consequences of lightheadedness and possible syncope.

    Hyperkalemia: Patients should be told not to use salt substitutes containing potassium without consulting their physician.

    Neutropenia: Patients should be told to promptly report any indication of infection (e.g., sore throat, fever), which could be a sign of neutropenia.

    Ramiprilum [Latin] Organismos afectados

    Humanos y otros mamíferos